Titan Biotech Reports 8% Revenue Growth and Board Changes in Q1 FY2026
Titan Biotech Limited reported a 7.8% increase in standalone revenue to Rs. 46.50 crore and an 8.1% rise in net profit to Rs. 6.16 crore for Q1 FY2026. The company appointed Mr. Debendra Kumar Sabat as Additional Independent Director and re-appointed Mr. Naresh Kumar Singla and Mr. Suresh Chand Singla as Managing Directors for five-year terms. A final dividend of Rs. 2.00 per share was recommended for FY2025. The 33rd Annual General Meeting is scheduled for September 26, 2025, with e-voting facilities available for shareholders.
*this image is generated using AI for illustrative purposes only.
Titan Biotech Limited , a leading biotechnology company, has announced its unaudited financial results for the first quarter ended June 30, 2025, along with significant board-level changes and dividend plans.
Financial Performance
The company reported a robust performance in Q1 FY2026:
- Standalone revenue increased by 7.8% to Rs. 46.50 crore, up from Rs. 43.11 crore in the same quarter last year.
- Net profit saw a notable rise of 8.1%, reaching Rs. 6.16 crore compared to Rs. 5.70 crore year-over-year.
- Earnings per share (EPS) improved to Rs. 7.46 from Rs. 6.90 in the previous quarter.
Board Appointments and Re-appointments
Titan Biotech has made several key changes to its board:
New Independent Director: Mr. Debendra Kumar Sabat has been appointed as an Additional Independent Director, effective August 13, 2025. Mr. Sabat brings over 20 years of legal expertise, with experience in finance, taxation, and corporate law.
Re-appointment of Managing Directors:
- Mr. Naresh Kumar Singla has been re-appointed as Managing Director for a five-year term from April 1, 2026, to March 31, 2031.
- Mr. Suresh Chand Singla has also been re-appointed as Managing Director for the same period.
Both re-appointments are subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Dividend Announcement
The Board of Directors has recommended a final dividend of Rs. 2.00 per share for the financial year ended March 31, 2025. The record date for dividend eligibility is set for September 19, 2025.
Annual General Meeting
Titan Biotech has scheduled its 33rd Annual General Meeting for September 26, 2025, to be held via video conferencing. Key dates include:
- AGM Date: September 26, 2025
- Record Date for Dividend: September 19, 2025
- Book Closure: September 21-26, 2025 (both days inclusive)
E-Voting Details
For shareholder convenience, the company has provided e-voting facilities:
- E-voting Cut-off Date: September 19, 2025
- Remote E-voting Period: September 22, 2025 (10:00 AM) to September 25, 2025 (5:00 PM)
Titan Biotech's strong Q1 performance, coupled with strategic board changes and shareholder-friendly initiatives, positions the company for continued growth in the biotechnology sector. Investors and stakeholders will be keenly watching the company's future developments and the outcome of the upcoming AGM.
Historical Stock Returns for Titan Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.98% | +26.35% | +103.08% | +113.75% | +29.10% | +518.67% |
19
